Variable |
N=80 |
Age, years, mean (SD) |
58.7 (12.2) |
Sex, female, n (%) |
52 (65.0) |
Smoking status, n (%)
Never smoked
Former (≥1 year)
Time since having quit smoking, years, mean (SD)
Current smoker
Packages/year, mean (SD)
|
61 (76.2)
13 (16.2)
11.7 (5.1)
6 (7.5)
21.5 (21.3)
|
Asthma history in the year before starting treatment with
omalizumab |
Asthma history in the year before starting
treatment with omalizumab |
Time since diagnosis of:
Asthma, years, median (Q1;Q3)
Severe persistent asthma, years, median (Q1;Q3)
|
12.9 (8.3; 23.3)
5.7 (4.4; 7.8)
|
Daytime symptoms, n (%)a
No symptoms or symptoms ≤2 times a week
>2 times a week
Daily symptoms
Continuous symptoms (several times a day)
|
3 (3.7)
15 (18.7)
43 (53.8)
18 (22.5)
|
Night-time symptoms, n (%)b
No symptoms
≤2 times a month
>2 times a month
> 1 time a week
Frequents
|
7 (8.9)
9 (11.4)
12 (15.2)
25 (31.6)
25 (31.6)
|
Need for rescue medication, n (%)a
No or ≤2 days a week
>2 days a week (but not every day)
Every day
Several times a day
|
6 (7.6)
22 (27.8)
41 (51.9)
10 (12.6)
|
Pulmonary function, median (Q1;Q3)a
FEV1, %
|
69.0 (58.0; 79.0)
|
Non-severe asthma episodes, median (Q1;Q3) |
5.0 (3.0;
8.0) |
Severe or clinically significant exacerbations in the previous year,
median (Q1;Q3)a
|
3.0 (2.0; 5.0) |
Use of healthcare resources due to severe or clinically significant
exacerbations, mean (SD)
Visits to emergency unitsb
Hospital admissions
No. days of hospital stayc
Intensive care units admission
No. days of intensive care units stayd
|
3.0 (2.8)
1.0 (1.9)
6.8 (3.2)
0.2 (0.6)
5.4 (3.9)
|
Background treatments for asthma, n (%)
ICS
Dose, µg, median (Q1; Q3)
OCSe
Dose, mg, median (Q1; Q3)
|
80 (100.0)
800 (640,0; 1,000.0)
54 (67.5)
25.0 (6.0; 50.0)
|
IgE levels, IU/mL, median (Q1;Q3) |
187.50 (106,0; 399,0) |